Blood transcriptomics reveal persistent SARS-CoV-2 RNA and candidate biomarkers in Long COVID patients

A recent groundbreaking study titled “Blood transcriptomics reveal persistent SARS-CoV-2 RNA and candidate biomarkers in Long COVID patients” has shed new light on the complexities of Long COVID, a condition affecting an estimated 65 million individuals globally. This medRxiv preprint, authored by Soraya Maria Menezes, Marc Jamoulle, Maria Paula Carletto, and others, represents a significant stride in understanding and potentially managing Long COVID.

The Study’s Core Findings:

  1. Persistent Viral RNA:
    • The study discovered systemic persistence of SARS-CoV-2, the virus responsible for COVID-19, for more than two years post-infection, highlighting the enduring nature of the virus in the human body.
  2. Diagnostic Biomarkers:
    • Researchers identified a two-gene biomarker, comprising FYN and SARS-CoV-2 antisense RNA, that can classify Long COVID with high sensitivity (93.8%) and specificity (91.7%). This discovery opens the door for non-invasive and accurate diagnostic tests.
  3. Correlation with Immune Response:
    • The study found specific immune transcripts and an immunometabolism score that correlates with the systemic viral load and patient-reported anxiety/depression, providing insights into the mechanism of Long COVID and its impact on mental health.

Methodology at a Glance:

The study utilized blood transcriptomics to explore viral persistence and potential diagnostic biomarkers for Long COVID in a real-world, general practice-based setting. Long COVID patients, diagnosed according to WHO criteria, were followed up for up to 39 months after their acute COVID-19 phase. Digital transcriptomic analysis was performed on blood samples from these patients and matched controls, focusing on differential gene expression and predefined biological pathway scores.

Unraveling the Complexity:

  1. Evidence of Ongoing Viral Replication:
    • The analysis revealed upregulated viral RNAs, including Nucleocapsid, ORF7a, ORF3a, Mpro, and antisense ORF1ab RNA, the latter suggesting ongoing viral replication.
  2. Immune System and Viral Load Connection:
    • The immunometabolism score was found to be negatively correlated with total blood viral load, indicating a potential link between metabolic status and ongoing viral replication.
  3. Impact on Patient Well-being:
    • The study observed a significant association between patient-reported emotional well-being (anxiety/depression scores) and both SARS-CoV-2 antisense RNA levels and the immunometabolism score.

The Path Forward:

While this study marks a significant advancement in understanding Long COVID, the authors note that the diagnostic biomarkers identified need to be validated in independent Long COVID cohorts. The findings provide a strong foundation for developing therapeutic strategies and non-invasive diagnostic tools, aiming to improve the clinical management of Long COVID.

This study underscores the importance of continued research and innovation in the fight against COVID-19 and its long-term impacts. As we move forward, the insights gained from this research hold the promise of better health outcomes for millions affected by Long COVID worldwide.

Read More: https://www.medrxiv.org/content/10.1101/2024.01.14.24301293v1.full.pdf

Leave a comment